Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Wells JA; Glassman AR; Ayala AR; Jampol LM; Aiello LP; Antoszyk AN; Arnold-Bush B; Baker CW; Bressler NM; Browning DJ; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW

doi:10.1056/nejmoa1414264

← Today's brief

Study

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Wells JA et al. · The New England journal of medicine · Wednesday, February 18, 2015

Funding Not reported

Source

Wells JA et al.. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine. Wednesday, February 18, 2015.
doi:10.1056/nejmoa1414264Read original ↗

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.